The Company's products stimulate cellular immunity by (1) initiating a TH1-specific cellular immune response where it is dormant or suppressed as in cancer, and (2) up-regulating the magnitude and effectiveness of an existing cellular immune response as during vaccine immunization. The Company's product portfolio is comprised of IRX-2 (citoplurikin), MIMP, and IRX-3, with several additional cancer therapy candidates in the pipeline.
| PRODUCT CANDIDATE | INITIAL INDICATION | STATUS |
| IRX- 2 | Head & Neck Squamous Cell Cancer | Phase 2 US Trial Complete Planning Global Phase 3 Trial |
| MIMP | Influenza in at risk population | Pre-clinical |
| IRX-3 | HIV/AIDS | Pre-clinical |
|
| 
